What are the advantages of monoclonal versus polyclonal antibodies as invigorating agents within cancer?
Monoclonal antibodies (identical antibodies of a single origin) are much more specific in their target. They are administered to a long-suffering whose cancer has be identified and its cellular markers are set. The antibodies bind those cancer-specific markers and signal the immune system to eradicate the cell. Polyclonal antibodies are used contained by instances where the physician isn’t entirely sure of the “strain” of cancer, but know its origination (ie kidney, pancreas, etc.) Polyclonal antibodies are several different antibodies engineered using the most common cancer cell marker, and are given to patients in the hopes that one will work. The efficacy between the two is fairly similar, but monoclonal is preferred.
